Asset Details
Do you wish to reserve the book?
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
Do you wish to request the book?
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase
2017
Overview
Introduction:
LY3045697 is a potent and selective aldosterone synthase (CYP11B2) inhibitor that was developed as a safer alternative to mineralocorticoid receptor antagonists. Effects of LY3045697 on aldosterone and cortisol synthesis, as well as potassium ion homeostasis, were evaluated in two clinical studies in healthy subjects.
Materials and methods:
Two incomplete, placebo-controlled crossover-design clinical studies examined safety, pharmacodynamics, and pharmacokinetics under single and repeated dose conditions in healthy subjects. Pharmacodynamics was assessed following oral potassium challenge and intravenous adrenocorticotropic hormone procedures with spironolactone 25 mg/d as an active comparator.
Results:
A total of 51 subjects participated in the two studies, which included 38 males and 13 females (of non-childbearing potential), from 18–65 years old. LY3045697 caused rapid dose and concentration-dependent unstimulated plasma aldosterone concentration reduction seen as early as 4 h after the first dose at dose levels as low as 1 mg, and reaching near complete suppression at high doses. The potency (IC50) decreased significantly upon multiple dosing. After eight days of dosing, post-adrenocorticotropic hormone challenge plasma aldosterone concentration increase was dose-dependently blunted by LY3045697 with high potency with a dose as low as 0.1 mg resulting in substantial effect, and with an overall IC50 of 0.38 ng/ml. Minor reductions in cortisol were observed only at the top dose of 300 mg. LY3045697 is generally safe and tolerated, and exhibits linear pharmacokinetics.
Conclusions:
LY3045697 is a potent and highly selective aldosterone synthase inhibitor with selectivity for CYP11B2, offering a substantial potential advantage over previous aldosterone synthase inhibitors evaluated in the clinic.
Publisher
SAGE Publications,Hindawi Limited
Subject
/ Adult
/ Aged
/ Arterial Pressure - drug effects
/ Cytochrome P-450 CYP11B2 - antagonists & inhibitors
/ Cytochrome P-450 CYP11B2 - metabolism
/ Dose-Response Relationship, Drug
/ Enzyme Inhibitors - adverse effects
/ Enzyme Inhibitors - pharmacokinetics
/ Enzyme Inhibitors - pharmacology
/ Female
/ Humans
/ Male
/ Original
